

UDSpace Institutional Repository
University of Delaware Open Access Articles

Kalburge, S., Carpenter, M., Rozovsky, S., & Boyd, E. (2017). Quorum Sensing Regulators Are Required for Metabolic Fitness in *Vibrio parahaemolyticus*. *Infection And Immunity*, 85(3), e00930-16.
<http://dx.doi.org/10.1128/iai.00930-16>

DOI: 10.1128/IAI.00930-16

© 2017 American Society for Microbiology

This article is made available in accordance with the University of Delaware Faculty Policy on Open Access ([4.2.15](#)) and the publisher's policy.

1 **Infection and Immunity**

7 **Quorum sensing regulators are required for metabolic fitness in**
 8 ***Vibrio parahaemolyticus***

10 **Sai Siddarth Kalburge^a, Megan R. Carpenter^a, Sharon Rozovsky^b and E.**
 11 **Fidelma Boyd^{a#}**

13 **Department of Biological Sciences, University of Delaware, Newark, DE 19716^a**
 14 **Department of Chemistry and Biochemistry, University of Delaware, Newark, Delaware,**
 15 **19716, United States^b**

18 Running title: quorum sensing regulators, carbon metabolism and transport, *Vibrio*
 19 *parahaemolyticus* intestinal colonization

21 #Corresponding author: E. Fidelma Boyd – fboyd@udel.edu

22 Department of Biological Sciences, 328 Wolf Hall, University of Delaware,
 23 Newark, DE 19716

24 Phone: (302) 831-1088. Fax: (302) 831-2281

25 **Abstract**

26 Quorum sensing (QS) is a process by which bacteria alter gene expression in response to cell
27 density changes. In *Vibrio* species, at low cell density, the sigma 54-dependent response
28 regulator LuxO, is active, and regulates the two QS master regulators AphA, which is induced
29 and OpaR, which is repressed. At high cell density the opposite occurs, LuxO is inactive,
30 therefore OpaR is induced and AphA is repressed. In *V. parahaemolyticus*, a significant enteric
31 pathogen of humans, the role of these regulators in pathogenesis is less known. We examined
32 deletion mutants of *luxO*, *opaR* and *aphA* for *in vivo* fitness using an adult mouse model. We
33 found that the *luxO* and *aphA* mutants were defective in colonization compared to wild-type. The
34 *opaR* mutant did not show any defect *in vivo*. Colonization was restored to wild-type levels in a
35 *luxO/opaR* double mutant and was also increased in an *opaR/aphA* double mutant. These data
36 suggest that AphA is important and that overexpression of *opaR* is detrimental to *in vivo* fitness.
37 RNA-seq analysis of the wild-type and *luxO* mutant grown in mouse intestinal mucus showed
38 that 60% of the genes that were downregulated in the *luxO* mutant were involved in amino acid
39 and sugar transport and metabolism. These data suggest that the *luxO* mutant has a metabolic
40 disadvantage, which was confirmed by growth pattern analysis using phenotype microarrays.
41 Bioinformatics analysis revealed OpaR binding sites in the regulatory region of 55 carbon
42 transporter and metabolism genes. Biochemical analysis of five representatives of these
43 regulatory regions demonstrated direct binding of OpaR in all five tested. These data
44 demonstrate the role of OpaR in carbon utilization and metabolic fitness, an overlooked role in
45 the QS regulon.

46

47 Introduction

48 *Vibrio parahaemolyticus* is the leading cause of bacterial seafood borne gastroenteritis
49 worldwide resulting in mild to severe inflammatory gastroenteritis (1-5). The completed genome
50 sequence of *V. parahaemolyticus* RIMD2210633, an O3:K6 serotype associated with pandemic
51 disease, demonstrated the presence of two type III secretion systems (T3SSs) one on each
52 chromosome, which led to the identification of several effector proteins associated with
53 inflammatory diarrhea (6-8). Studies have shown that T3SS-2 is the major contributing factor
54 towards enterotoxicity and that inflammatory diarrhea and intestinal epithelium cell disruption
55 are dependent upon a functional T3SS-2 (9-12).

56 Much less is known about how *V. parahaemolyticus* initially colonizes and survives
57 within the host gastrointestinal tract. This lack of knowledge is in part due to a lack of animal
58 models to study colonization and infection *in vivo*. The development of a streptomycin
59 pretreated adult mouse model that removes microbiota colonization resistance and allows *V.*
60 *parahaemolyticus* to colonize has uncovered a number of bacterial colonization factors required
61 for colonization (13-15). Examination of a mutant deficient in the global regulator ToxR
62 demonstrated a significant defect in intestinal colonization compared to the wild-type (13). This
63 study showed that ToxR was a negative regulator of the global regulator LeuO and a positive
64 regulator of T3SS-1 and the major outer membrane porin OmpU (13). OmpU was shown to be
65 essential for resistance and tolerance to acid and bile salts, important abiotic stresses *in vivo* (13).
66 The importance of ToxR for *in vivo* survival also was demonstrated in an infant rabbit model of
67 infection (16). The alternative sigma factor RpoE, required for the cell envelope stress response,
68 was shown to be essential for *in vivo* survival, as deletion of the *rpoE* gene resulted in
69 attenuation of mouse colonization (15). In contrast, analysis of a deletion mutant of sigma-54,

70 *rpoN* showed that in *in vivo* competition assays, the mutant colonized significantly more
71 proficiently than the wild-type strain. The mechanism for the enhanced colonization of the *rpoN*
72 mutant is unknown, however, it was shown that the *rpoN* mutant had a metabolic advantage over
73 wild-type when grown in intestinal mucus and its components. Expression analysis showed that
74 genes required for gluconate, ribose and arabinose catabolism were induced in the *rpoN* mutant.
75 These data suggested that specific carbon metabolism genes are negatively regulated by RpoN
76 and that competitive carbon utilization could be an important colonization factor (14).

77 Quorum sensing is a process by which bacteria modulate gene expression in response to
78 cell density changes and is mediated by autoinducers such as acyl homoserine lactone that act as
79 extracellular signals (17-22). Quorum sensing has been studied in a number of *Vibrio* species
80 including *V. parahaemolyticus*, which contains the central conserved components of the quorum
81 sensing pathway identified in *V. harveyi* (**Fig. 1**) (22-34). In *V. harveyi*, quorum sensing
82 regulation of gene expression is carried out by two quorum sensing master regulators, the low
83 cell density (LCD) regulator AphA and the high cell density (HCD) regulator, LuxR. At LCD,
84 when the autoinducer concentration is low, LuxO, the QS response regulator is active and
85 functions as an activator for sigma factor RpoN (δ^{54}) that then aids in the transcription of five
86 small RNAs termed quorum regulatory RNAs (*qrr*) 1-5(35, 36). Qrrs are bacterial sRNAs that
87 are partially complimentary to their target mRNA and thereby regulate gene expression post-
88 transcriptionally. They require the sRNA chaperone Hfq for their activity (36-38). Qrrs were
89 identified first in *V. cholerae* where they were shown to repress HapR (the LuxR homologue)
90 through direct base pairing (37). The Qrrs stabilize the mRNA of *aphA* and destabilize the
91 mRNA of *luxR*. In addition, AphA represses *luxR* transcription, independent of the Qrrs (36, 39,
92 40). At HCD, LuxO is not active, the *qrrs* are not transcribed, leading to a constitutively

expressed LuxR, which in turn represses the transcription of *aphA* (Fig. 1) (36, 39, 40). The *V. parahaemolyticus* genome contains each of the components described above, *luxO*, *qrr1* to *qrr5*, *aphA* and *opaR*, the *luxR* homologue in this species (25, 30, 37, 41, 42 Zhang, 2012 #25). LuxR and OpaR regulate 100s of genes in *V. harveyi* and *V. parahaemolyticus*, respectively (30, 39, 42). OpaR was shown to positively regulate capsule polysaccharide (CPS) production, competence, and type VI secretion system-2 (T6SS-2) production and negatively regulate motility, biofilm, and T3SS-1 and T6SS-1 production (30, 32-34, 41-43). AphA was shown to regulate several genes in various *Vibrio* species including genes involved in biofilm formation, motility and virulence (39, 44-46). In *V. harveyi*, AphA coregulated a number of genes including the T3SS apparatus along with LuxR (39). In *V. parahaemolyticus*, AphA is required for motility, biofilm formation and an *aphA* mutant strain is avirulent in a murine infection model (41).

In this study, we determined the role of the QS regulators in *V. parahaemolyticus* intestinal colonization, the first step in pathogenesis. We constructed a *luxO* deletion mutant and *in vivo* analysis showed that the mutant had a significant defect in a streptomycin pretreated adult mouse model of colonization. We determined whether the defect in the *luxO* mutant was through its regulation of the QS regulators OpaR or AphA by constructing deletions in each of these genes as well as double deletion mutants and examined the *in vivo* phenotypes. The *aphA* mutant was attenuated for colonization similar to the *luxO* mutant, whereas the *opaR* mutant showed no defect in colonization. Double deletion mutants *luxO/opaR* and *opaR/aphA* showed significantly increased colonization abilities compared to the single *luxO* or *aphA* deletion mutants. These results suggested that AphA is important for *in vivo* fitness likely in part through its negative regulation of *opaR* and that over expression of *opaR* is detrimental. Comparative transcriptome

116 analysis of wild-type versus the *luxO* mutant grown in mouse intestinal mucus showed 60% of
117 genes downregulated in the *luxO* mutant were involved in metabolism. Using phenotype
118 microarrays, we found significant differences in growth between the wild-type and *luxO* and
119 *aphA* mutant strains in 25 carbon sources. Bioinformatics analysis identified putative OpaR
120 binding sites in the regulatory regions of carbon metabolism and transporter genes. By using
121 electrophoretic mobility shift assays, we show direct binding to five of these regulatory regions.
122 Overall, the data demonstrate a direct role for the QS regulator OpaR in cell metabolism and
123 suggests a mechanism for the *in vivo* phenotypes of the *luxO* and *aphA* mutants.

124

125 **Material and Methods**

126 **Bacterial strains, media and culture conditions.** All the strains and plasmids used in this study
127 are listed in **Table S1**. A streptomycin-resistant strain of *V. parahaemolyticus* O3:K6 clinical
128 isolate RIMD2210633 was used throughout this study (13, 47). For competition experiments a β -
129 galactosidase-positive strain of RIMD2210633, named WBWlacZ was used. Colonies of the
130 WBWlacZ strain appear blue on an X-gal plate in comparison to the wild-type and its isogenic
131 mutants that appear white on the plate, thus allowing for a blue: white screen in a competition
132 experiment. The WBWlacZ was previously shown to behave identical to wild-type *in vitro* and
133 *in vivo* (13, 14). Unless stated otherwise, all *V. parahaemolyticus* strains were grown in
134 Lysogeny Broth (LB) containing 3% NaCl (LBS) (Fischer Scientific, Pittsburgh, PA) at 37°C
135 with aeration. For growth studies, M9 medium (Sigma Aldrich, St. Louis, MO) supplemented
136 with 3% NaCl was used to which different carbon sources were added. For genetic
137 manipulations, an *Escherichia coli* diaminopimelic acid (DAP) auxotroph β 2155 λ pir was used.

138 The *E. coli* β 2155 λ pir strain was cultured in LB medium supplemented with 0.3 mM DAP
139 (Sigma Aldrich). When required, antibiotics were used at the following concentrations:
140 streptomycin, 200 μ g/ml; chloramphenicol, 25 μ g/ml; ampicillin 100 μ g/ml.

141 **Construction of *V. parahaemolyticus* RIMD2210633 quorum sensing deletion mutants.**

142 Splicing by overlap extension (SOE) PCR with homologous recombination (48) was used to
143 construct in-frame nonpolar deletions in VP2099 (*luxO*), VP2762 (*aphA*), VP2516 (*opaR*) and
144 double deletion mutants *luxO/opaR* and *opaR/aphA* as previously described by this group (13-15,
145 47, 49). Primers were designed to the QS response regulator *luxO* and the two QS master
146 regulators *opaR* and *aphA* using the *V. parahaemolyticus* RIMD2210633 genome sequence as
147 the template. All primers used in the study are listed in **Table S2** and SOE PCR was performed
148 to obtain a 75-bp truncated version of the 1,362-bp *luxO* gene, a 39-bp truncated version of the
149 615-bp *opaR* gene and a 48-bp truncated version of the 540-bp *aphA* gene. All mutants were
150 confirmed by PCR analysis and were verified to be in-frame by sequencing.

151 ***In vivo* competition assays.** All experiments involving mice were approved by the University of
152 Delaware Institutional Animal Care and Use Committee. Male C57BL/6 mice, aged 6 to 10 wk
153 were housed under specific-pathogen-free conditions in standard cages in groups (4 or 5 per
154 group) and provided standard mouse feed and water *ad libitum*. Streptomycin pre-treatment and
155 inoculations were performed as previously described (13, 14). Briefly, 24 h before bacterial
156 inoculations by oral gavage, mice were fasted for 4 h and then administered 20 mg streptomycin
157 per animal orogastrically and then food and water were immediately returned. Four hours prior
158 to inoculation food and water were removed. Water was restored immediately upon inoculation
159 and food was restored 2 h post-infection. The *V. parahaemolyticus* strain used for *in vivo*
160 experiments is the β -galactosidase knock-in designated WBWlacZ, which allows for a blue:white

161 colony screening (13-15). Overnight cultures were diluted 1:50 with LBS streptomycin media
162 and grown for 4 h at 37°C with aeration. An aliquot of the 4 h culture was pelleted and
163 resuspended in PBS to a final concentration of $\sim 1 \times 10^{10}$ CFU/ml. A 1 ml aliquot of each deletion
164 mutant strain was combined with 1 ml of the WBWlacZ strain, yielding a bacterial suspension of
165 $\sim 1 \times 10^{10}$ CFU/ml with a ratio of 1:1 CFU of mutant to WBWlacZ strain. Mice were inoculated
166 with 100 μ l of the appropriate bacterial suspension. An aliquot of the inoculum was serially
167 diluted and plated onto LBS plates with streptomycin and X-gal in order to determine the exact
168 ratio of CFUs in the inoculum. For *in vitro* competition assays, a 100 μ l aliquot of the *in vivo*
169 inoculum was added to 5 ml of LBS, grown at 37°C with aeration for 24 h and serially diluted
170 and plated. The mice were sacrificed 24 h post infection and the gastrointestinal tract was
171 harvested and suspended in 8 ml of sterile PBS, homogenized mechanically, serially diluted and
172 plated on LBS plates containing 120 μ g/ml X-gal and incubated at 37°C overnight. The
173 competitive index (CI) for the *in vivo* and *in vitro* assays was determined with the following
174 equation: $CI = \text{ratio out}_{(\text{mutant/wild-type})} / \text{ratio in}_{(\text{mutant/wild-type})}$. A CI >1 indicates that the test strain
175 has the ability to out-compete the wild-type strain, while a CI of <1 indicates that the test strain
176 is less fit than the wild-type strain.

177 **Capsule polysaccharide (CPS) production and biofilm assays.** CPS production was examined
178 using heart infusion (HI) (Remel, Lenexa, KS) plates containing 1.5% agar, 2.5 mM CaCl₂, and
179 0.25% Congo red dye. Single colonies were inoculated onto the surface of the plates and were
180 incubated at 30°C for 36 h before images were taken. Biofilm formation was examined using the
181 crystal violet assay. Briefly, overnight cultures of *V. parahaemolyticus* were diluted 1:40 into
182 LBS and grown statically in 96-well strip plates at 37°C for 3, 6, 12 and 24h. After static
183 incubation, the culture was decanted from each well and the well was washed once with sterile

184 phosphate buffered saline (PBS). Crystal violet was added into each well and the plate was
185 incubated at room temperature for 30 min. The crystal violet was decanted out and the well was
186 washed with sterile PBS. The PBS was then decanted out and crystal violet that had stained the
187 adherent cells was solubilized completely in dimethylsulfoxide (DMSO) and the optical density
188 (OD_{595}) was measured to quantify the amount of biofilm formed.

189 **RNA extraction, Illumina sequencing and quantitative real time PCR (qPCR).** *Vibrio*
190 *parahaemolyticus* wild-type and mutant strains were grown for 4 h in LBS and then diluted 1:50
191 into M9 medium supplemented with mouse intestinal mucus as the sole carbon source and the
192 cells were grown statically. We examined early-exponential-phase cultures that were grown for
193 1.5 h, considering the low cell density condition would restrict *opaR* levels in the wild-type,
194 thereby allowing us to observe the greatest difference in *opaR* levels between the *luxO* mutant
195 and wild-type. Total RNA was extracted from cells obtained by centrifugation at the end of 1.5 h
196 using Trizol (Invitrogen, Carlsbad, CA) according to manufacturer's protocol. The RNA samples
197 were then quantified using a Nanodrop spectrophotometer (Thermo Scientific, Waltham, MA).
198 The samples were treated with Turbo DNase (Invitrogen) according to manufacturer's
199 instructions. For each sample of the wild-type and mutant, RNA samples from two independent
200 cultures were pooled together. Nanodrop quantifications were used to ensure equal
201 representation of RNA from both biological replicates. Then, 3 μ g of RNA was used for rRNA
202 depletion using the Ribo-Zero rRNA removal kit for Gram-negative bacteria (Illumina, San
203 Diego, CA). Libraries for each sample were prepared from 100ng of rRNA-depleted-RNA using
204 the Illumina TruSeq Stranded mRNA kit (Illumina). Sequencing was performed at the University
205 of Delaware Sequencing and Genotyping Center on the HiSeq 2500 platform to yield 51-base
206 single-end reads.

207 For qPCR validations of the RNA-Seq, 500 ng of pre-ribozero treated RNA was used as a
208 template for cDNA synthesis. cDNA was synthesized using Superscript III reverse transcriptase
209 (RT) (Invitrogen) following manufacturer instructions using 500 ng of RNA template and
210 priming with 200 ng of random hexamers. cDNA samples were then diluted 1:25 and used for
211 quantitative-real time PCR (qPCR). To analyze expression of the wild-type and mutant strains at
212 HCD, cells were grown for 4 h in LBS medium and were then diluted 1:50 into M9 medium
213 containing 3% NaCl and supplemented with glucose (M9G) and grown to an OD of 1.0. Total
214 RNA was extracted using the Trizol extraction protocol detailed above. 500 ng of the DNase
215 treated RNA samples were used as template for cDNA synthesis. cDNA samples were then
216 diluted 1:25 or 1:10 and used for quantitative-real time PCR (qPCR). Fast SYBR Green master
217 mix or PowerUp SYBR Green master mix (Life Technologies, Carlsbad, CA) was used for
218 qPCR and samples were run on an Applied Biosystems 7500 fast real-time PCR system or
219 QuantStudio 6 Flex real-time PCR system (Applied Biosystems, Foster City, CA). Each
220 experiment was performed in duplicate with at least two biological replicates. Primers used for
221 the qPCR reactions are listed in **Table S2**. Data was analyzed using Applied Biosystems
222 software. Expression levels of each gene as determined by their cycle threshold (C_T) values,
223 were normalized using the 16s rRNA housekeeping gene to correct for sampling errors.
224 Differences in the ratios of gene expression were determined using the $\Delta\Delta C_T$ method (50).

225 **RNA-Seq analysis.** Raw 51-base reads were filtered to remove adaptor only sequences and low
226 quality reads using the FASTX Toolkit. Filtered reads were aligned to the *V. parahaemolyticus*
227 RIMD2210633 genome (Refseq ID NC_004603.1 Chromosome 1 and NC_004605.1
228 Chromosome 2) using Burrows-Wheeler Aligner (BWA.aln) version 0.7.7. Gene annotations
229 were obtained from Ensembl bacteria, Rfam, Bacterial Small Regulatory RNA database and

230 RAST. Number of reads aligning to each genomic position were calculated using Htseq version
231 0.6.1. Differential expression analysis was performed on obtained read counts using DESeq2
232 version 1.4.5. Differential expressed genes were categorized into Cluster of orthologous groups
233 (COG) obtained from Integrated Microbial Genomes (IMG) database.

234 **Growth analysis and *in vitro* competition assays.** Strains were grown overnight in M9G at
235 37°C with aeration. For the Biolog PM1 and PM2A phenotype microarrays (Biolog Inc.,
236 Hayward, CA), overnight cultures were then diluted 1:50 into fresh M9G and allowed to grow
237 for 4 h. These cultures were pelleted by centrifugation for 10 min at 4,000 x *g*, washed twice
238 with PBS and then diluted 1:50 into fresh M9 media supplemented with 3% NaCl and 100 µl
239 was then added to each well of the Biolog plate. Plates were incubated at 37°C with intermittent
240 shaking for 1 min. during every hour. Optical densities at 595 nm were taken hourly for a total of
241 24 h using a Tecan Sunrise microplate reader and Magellan plate reader software (Tecan
242 Systems Inc., San Jose, CA). Growth characteristics were analyzed by calculating Area under the
243 curve using the Origin 8.5 software. The Area under the curve for the blank well was subtracted
244 from each well to perform the analysis. For growth curves in individual mucus sugars and amino
245 acids, 4 h cultures were pelleted, washed and were diluted 1:40 in M9G (10 mM), M9 D-
246 Gluconate (10 mM), D-Mannose (10 mM), D-Ribose (10 mM), L-Arabinose (10 mM), D-
247 Galactose (10 mM), D-Glucosamine (10 mM), Pyruvic acid (10 mM), D-Trehalose (10 mM),
248 Fructose (10 mM), L-Glutamic acid (5mM), or L-Aspartic acid (30 mM). Mouse intestinal
249 mucus was extracted as described previously (14, 15). Mice gastrointestinal tracts were harvested
250 and then flushed with PBS to remove intestinal contents. Mucus was collected and pooled by
251 gently scraping the surface walls of the intestine using a spatula or blunted blade. The collected
252 mucus was suspended in PBS and vortexed until homogenized. The mucus solution was then

253 centrifuged at 500 x *g* for 10 min and the supernatant collected. Protein concentration was
254 determined using a Bradford assay. Approximately 30 µg/ml of protein was used in M9 medium
255 for experiments involving mucus (14, 51, 52). Each experiment was performed in triplicate with
256 at least two biological replicates. *In vitro* competition assays in mucus and mucus sugars were
257 performed with inoculums prepared as described for *in vivo* competition assays. 100 µl aliquot of
258 the inoculum was added to 5 ml of M9 minimal media supplemented with 10mM of individual
259 mucus sugars or 30 µg/ml of intestinal mucus and grown at 37°C with aeration for 24 h, serially
260 diluted and plated. Competitive index for each assay was calculated as detailed above.

261 **Bioinformatics analysis of OpaR and AphA binding sites.** The consensus binding sequence
262 and position frequency matrix was obtained for OpaR (33) and AphA (53). The position
263 frequency matrix was then used to identify potential binding sites using the MOODS (Motif
264 Occurrence Detection Suite) algorithm (Version 1.0.2.1) (54, 55). The upstream intergenic
265 sequence for the first gene of each operon was obtained from the NCBI database and used to
266 identify putative binding sites. Operon information was obtained from the DOOR2 prokaryotic
267 operon database (56) and was confirmed using the IGV viewer (57) with the RNASeq sequence
268 data. The MOODS tool returned a Log-odds score for each putative binding site that was then
269 used to access probability of binding.

270 **Purification of OpaR.** OpaR was purified using a method previously described (58). Briefly,
271 *opaR* was cloned into the pProEX HTa expression plasmid (Invitrogen) in which an N-terminal
272 6x His tag is fused to *opaR*, separated by a Tobacco Etch Virus (TEV) protease cleavage site.
273 The primer pair SfoIVP2516Fwd/SacIVP2516Rev (**Table S2**) was used to amplify *opaR*
274 (VP2516) from the *V. parahaemolyticus* RIMD2210633 genome using Accura HiFidelity
275 Polymerase (Lucigen, Middleton, WI) following manufacturer's instruction. The *opaR* PCR

276 product was gel cut purified using the Nucleospin Gel and PCR cleanup kit (Macherey-Nagel)
277 and cloned into pJET1.2 using the blunt end ligation protocol. This was transformed into *E. coli*
278 Dh5 α using standard CaCl₂ transformation protocol. Plasmid DNA was isolated, restriction
279 digested and ligated into pProEX HTa plasmid. The ligation product was transformed into *E. coli*
280 DH5 α and plasmid DNA was isolated and confirmed by sequencing before being transformed
281 into *E. coli* BL21(DE3) using standard CaCl₂ method. The pProExHtaOpaR plasmid was
282 expressed in *E. coli* BL21(DE3). A volume of 10 mL overnight culture was inoculated into 1 L
283 LB broth at 37°C and induced with 0.5 mM isopropyl-1-thio- β -d-galactopyranoside (IPTG) at
284 OD₆₀₀ 0.5. Growth continued overnight at 18°C. Cells were harvested by centrifugation (5,000 x
285 g for 20 min at 4°C) and were re-suspended in immobilized metal affinity chromatography
286 (IMAC) Wash Buffer (50 mM sodium phosphate, 200 mM NaCl, 20 mM imidazole, pH 7.6)
287 supplemented with the protease inhibitors 1 mM phenylmethanesulfonyl fluoride (PMSF) and 1
288 mM benzimidazole. Bacterial cells were lysed on ice using a high-pressure homogenizer
289 (EmulsiFlex-C5, Avestin, Ottawa, Canada). Cell debris was removed by centrifugation (15,000 x
290 g for 1 h at 4°C). The supernatant was passed through a column containing 5 mL Profinity
291 IMAC resin (Bio-Rad Laboratories, Hercules, CA). The column was washed with 10 column
292 volumes (CV) of IMAC Wash Buffer. The fusion protein, 6xHis-OpaR was eluted with three CV
293 IMAC Elution Buffer (50 mM sodium phosphate, 200 mM NaCl, 500 mM imidazole, pH 7.6). A
294 hexahistidine-tagged TEV protease was added to the eluent in a 1:10 molar ratio (TEV: 6xHis-
295 OpaR) and the cleavage reaction proceeded overnight at 4°C. The cleavage mixture was
296 centrifuged, adjusted to 20 mM imidazole and subject to IMAC using Profinity IMAC resin to
297 remove the His-tagged TEV and any remaining un-cleaved fusion protein. The flow through and
298 one CV of wash with IMAC Wash Buffer contained OpaR. The fractions were combined,

299 concentrated and the buffer exchanged to that of the electrophoretic mobility shifts assays
300 binding buffer (10 mM Tris, 150 mM KCl, 0.1 mM dithiothreitol, 0.1 mM EDTA, 5% PEG, pH
301 7.4). The protein identity was confirmed by mass spectrometry and its purity was determined to
302 be higher than 95% by SDS-PAGE.

303 **Electrophoretic Mobility Shift Assays.** DNA probes VP0008 (amino acid transport), VP1779
304 (putrescine metabolism), VPA1087 (ribose transport), VPA0500 (mannitol PTS transporter),
305 VPA1424 (mannose metabolism) and negative control VPA1667 (glucose-specific PTS
306 transporter), were PCR amplified using Accura HiFidelity Polymerase in 50 μ l reactions using
307 corresponding primer sets in **Table S2** with *V. parahaemolyticus* DNA as template. PCR
308 products were separated on a 1% agarose gel and bands excised from the gel were purified using
309 NucleoSpin Gel and PCR clean-up kit (Macherey-Nagel). Purified DNA probes were quantified
310 using a Nanodrop spectrophotometer. Varying concentrations of purified OpaR were incubated
311 with 30 ng of target DNA in binding buffer (10 mM Tris, 150 mM KCl, 0.1 mM dithiothreitol,
312 0.1 mM EDTA, 5% PEG, pH 7.4) for 20 min at room temperature and 10 μ L were loaded onto a
313 pre-run (200 V for 2 h at 4°C) 6% native acrylamide gel. The gel was run at 200 V for 3 h in 1x
314 Tris-acetate-EDTA (TAE) buffer at 4°C. Following electrophoresis, gels were stained in an
315 ethidium bromide bath (0.5 μ g/ml) for 20 min, washed with water and imaged.

316 **Results**

317 **Deletion of *luxO* or *aphA* leads to a defect in intestinal colonization.** To determine the role of
318 the QS regulators in *V. parahaemolyticus* pathogenesis, we examined each of the QS mutants for
319 their ability to colonize the adult mouse intestine. We examined *luxO*, *aphA* and *opaR* deletion
320 mutant strains as well as double deletion mutants *luxO/opaR* and *opaR/aphA* in *in vivo*
321 competition assays with wild-type using the streptomycin pretreated adult mouse model of

322 intestinal colonization (13, 14). Mice pretreated with streptomycin were orogastrically co-
323 inoculated with an equal mixture of WBWlacZ (wild-type marked with *lacZ*) and each of the
324 mutants. In these assays, the WBWlacZ strain significantly out-competed the *luxO* mutant,
325 which had a competitive index (CI) of 0.27 indicating that deletion of *luxO* leads to reduced
326 fitness *in vivo* (**Fig. 2**). In order to investigate whether the defect in the *luxO* mutant was through
327 its regulation of the QS regulators AphA or OpaR, we constructed deletion mutants in each of
328 these genes. The *aphA* mutant showed a significant defect in colonization similar to the *luxO*
329 mutant with a CI of 0.39 (Fig 2). Both the *luxO* and *aphA* mutant strains grew similar to wild-
330 type in *in vitro* competition assays in LBS, with CIs of 0.9 and 1.0 respectively. These data show
331 that deletion of *luxO* or *aphA* affects colonization ability specifically (**Fig 2**). The *opaR* mutant
332 behaved similar to the wild-type in both *in vitro* and *in vivo* assays with a CI of ~1. In order to
333 determine further the importance of each of these regulators in colonization, we examined double
334 deletion mutants, *luxO/opaR* and *opaR/aphA*. The deletion of *opaR* in the *luxO* and *aphA* mutant
335 resulted in a significant increase in colonization ability compared to the single *luxO* and *aphA*
336 mutants. Colonization was restored to wild-type levels in the *luxO/opaR* double mutant, which
337 had a CI of 1.4. The *opaR/aphA* mutant also had increased colonization compared to the *aphA*
338 single mutant with a CI of 0.7, however, this mutant still showed a defect in colonization
339 compared to wild-type. (**Fig. 2**). Taken together, these data demonstrate that over-expression of
340 OpaR in the mutant compared to wild type is detrimental and AphA is required for *in vivo*
341 colonization.

342 The *in vivo* defect observed for the *luxO* mutant is in contrast to the superior colonization
343 phenotype that we had previously showed for an *rpoN* deletion mutant (14). According to the
344 quorum sensing pathway in *V. parahaemolyticus*, deletion of both *luxO* and *rpoN* should have

345 the same effect on the expression of the two master regulators *aphA* and *opaR*. We determined
346 the expression patterns of these regulators in *luxO*, *opaR*, *aphA* and *rpoN* mutant strains grown to
347 OD 1.0 in M9G. Expression of *opaR* was significantly induced in the *luxO* mutant with a 6.3-
348 fold change in expression relative to wild-type. The expression of *opaR* was increased in both the
349 *rpoN* and the *aphA* mutants, but not to the same level as in the *luxO* mutant (**Fig. 3A**).
350 Expression of *aphA*, although not significant, was reduced in the *luxO* mutant and was induced
351 in the *opaR* mutant. The expression of *aphA* was not repressed in the *rpoN* mutant (**Fig. 3B**).
352 Both RpoN and its activator LuxO are required for the *qrrs* expression since *qrr1* to *qrr5* each
353 contain a conserved RpoN -12 and -24 promoter binding sequence indicating this sigma factor is
354 involved in expression (35). To address why *aphA* was not repressed and *opaR* is not as highly
355 expressed in the *rpoN* mutant compared to the *luxO* mutant, we examined the expression patterns
356 of *qrr1* to *qrr5* in both these mutants under the same conditions as *opaR* expression. QPCR
357 analysis showed that in the *luxO* mutant compared to wild-type, *qrr2*, *qrr3* and *qrr5* were
358 repressed, while *qrr1* was unchanged (**Fig. 3C**). In the *rpoN* mutant, qPCR analysis showed that
359 *qrr1*, *qrr3* and *qrr5* were repressed, however *qrr2* was not repressed compared to wild-type (**Fig.**
360 **3D**). In both cases, *qrr4* expression was either very low or altogether not detected. The most
361 notable difference in expression patterns between the *luxO* and *rpoN* mutants was in *qrr2*. While
362 *qrr2* was significantly downregulated in the *luxO* mutant, its expression was not repressed in the
363 *rpoN* mutant. We speculate that the differential expression of *qrr2* in the *rpoN* mutant may
364 explain the reduced level of *opaR* compared to the *luxO* mutant.

365 The *V. parahaemolyticus* quorum sensing master regulators OpaR and AphA have been
366 shown to regulate CPS production and biofilm formation (25, 30, 41, 59, 60). We examined
367 these phenotypes in the QS regulator mutants examined in this study. The *luxO* and *aphA*

368 mutants produced rugose colonies similar to wild-type indicating CPS production, which
369 indicates that CPS production is not involved in the *in vivo* phenotype of these mutants (**Fig.**
370 **S1A**). The *luxO* and *aphA* mutants produced similar amount of biofilm as wild-type at the initial
371 time points but were found to be defective at 24 h (**Fig S1B**). Previously, we showed that an
372 *rpoN* mutant had a defective in biofilm formation but had a superior colonization phenotype
373 suggesting this is not the cause of the *luxO* and *aphA* mutants *in vivo* phenotypes.

374 **RNA-seq data and comparative analysis of gene expression in mouse intestinal mucus.** To
375 begin to determine the mechanism of the *in vivo luxO* mutant colonization defect, we performed
376 RNA-Seq expression analysis of the wild-type and the *luxO* mutant strains. RNA was isolated
377 from both strains grown to early exponential phase in M9 supplemented with mouse intestinal
378 mucus as the sole carbon source. The LCD time point was chosen since it should show
379 maximum differences in *opaR* expression between the wild-type (low OpaR levels) and the *luxO*
380 mutant (high OpaR levels). Sequencing resulted in greater than 10 million sequence reads
381 obtained for each sample (**Fig. S2A**). Over 98% of the reads aligned to genomic features
382 including mRNA, tRNA, sRNA or to unannotated regions of the genome. The rRNA depletion
383 procedure resulted in less than 0.5% of the reads aligning to these features in the genome (**Fig.**
384 **S2A and S2B**). Differential expression analysis revealed that 106 genomic features and 102
385 features were downregulated and upregulated (> 2 -fold, $P_{\text{adj}} < 1 \times 10^{-4}$) respectively in the *luxO*
386 mutant compared to wild-type (**Fig. S3, Table S3 and S4**). Of the total 208 differentially
387 regulated features, 134 were from chromosome I and 74 were from chromosome II (**Table S3**
388 **and S4**). The 106 downregulated features were all annotated ORFs. The 102 upregulated
389 features included 93 annotated ORFs, 3 small RNAs and 6 tRNAs. The *opaR* gene was induced
390 and *aphA* was repressed in the *luxO* mutant compared to wild-type and this was confirmed by

391 qPCR (**Fig. 4A**). Expression analysis of the *qrrs* by qPCR showed that *qrr5* was significantly
392 downregulated in the *luxO* mutant (**Fig. 4A**). Twenty-one of the genes upregulated in the *luxO*
393 mutant belonged to the T6SS-2 region on chromosome II (VPA1024 - 44), which was previously
394 shown to be positively regulated by OpaR (30). QPCR analysis of VPA1027 (*hcp2*) from the
395 T6SS-2 cluster confirmed that in the *luxO* mutant this gene was induced (**Fig. 4C**). Furthermore,
396 qPCR analysis of *hcp1* (VP1393) from the T6SS-1 cluster and *yopD* (VP1656) from the T3SS-1
397 cluster showed their expression was reduced compared to wild-type (**Fig. 4C**). The most highly
398 upregulated genes in the *luxO* mutant were genes for the replication and synthesis of the
399 filamentous phage f237 (VP1550-VP1562). Many genes within the class-1 integron region on
400 chromosome I (VP1790-VP1851) were also induced in the *luxO* mutant compared to wild-type
401 (Table S3A). The majority of the genes within the f237 phage and the class-1 integron were
402 categorized into the COG classes S: Function unknown and R: General function prediction only
403 (**Fig. S4A**). The T6SS-2 genes were classified into the COG class U: Intracellular trafficking,
404 secretion and vesicular transport (**Fig. S4A**). Among the downregulated COG classes, most
405 interesting to note was that 60% of the genes were classified into categories involved in
406 metabolism and transport (**Fig. S4B**).

407 **Metabolism and transporter genes are downregulated in the *luxO* mutant.** Of the 106
408 genomic features downregulated in the *luxO* mutant, 64 genes were involved in transport and
409 metabolism of amino acids, carbohydrate and lipids (**Fig S4B and Table S4**). Downregulated
410 gene clusters that comprised amino acid transport and metabolism included arginine biosynthesis
411 (VP2756-VP2760) and transport (VPA0637-VPA0639) (**Fig S4A**), phenylalanine/ tyrosine
412 biosynthesis (VP0546-VP0547, VP0555) and histidine biosynthesis (VP1137-VP1138). QPCR
413 analysis confirmed the downregulation of VP2756 (*argH*), an ORF in the arginine biosynthesis

(VP2756-VP2760) pathway (**Fig. 4B**). The carbohydrate metabolism and transport genes downregulated in the *luxO* mutant included genes involved in D-mannitol metabolism (VPA0501-0502), D-galactose degradation (VP2397-VP2400) and L-arabinose transport and metabolism (VPA1671-VP1677) (**Table S4**). QPCR analysis confirmed the downregulation of VPA1674 (*araB*), an ORF in the arabinose catabolism pathway (**Fig. 4B**). A region required for tetrathionate reductase synthesis (VP2012-VP2016) was also repressed in the *luxO* mutant compared to wild-type. Tetrathionate can be used as an electron donor that is produced in vertebrate intestinal mucosa from thiosulphate by the action of tetrathionate reductase (61). VP1771-VP1779 and VP1781-VP1782 are two operons involved in the polyamine putrescine utilization and all ORFs within this region were downregulated in the *luxO* mutant, which was confirmed by qPCR analysis of VP1779 (*puuD*) (**Fig. 4B**). ORFs VP1447 to VP1451 are homologs of genes required for the synthesis of a putative anaerobic dimethyl sulfoxide reductase and these genes were all downregulated in the *luxO* mutant. There were eight putative transcription regulators downregulated in the *luxO* mutant compared to wild-type, VP0358 (DeoR), VP1778 (PuuR), VP3009 (AraC/XylS family), VPA0053 (TetR family), VPA0251 (LysR family), VPA0717 (LysR family), VPA0883 (LysR family), and VPA1678 (AraC/XylS family). In addition, genes for compatible solute biosynthesis were also downregulated, two genes in the ectoine biosynthesis pathway (VP1721-VP1720) and two genes involved in betaine biosynthesis (VPA1112) and transport (VPA1111) operon (**Table S4**).

Growth comparisons of wild-type and mutant strains on different carbon sources. Our RNA-seq data suggests that *luxO* could be at a metabolic disadvantage given the down regulation of many metabolism and transporter genes. Thus, the growth patterns of the wild-type and QS mutants were examined in 190 carbon sources to determine whether there were differences

among the strains. A total of 71 different carbon sources were utilized by wild-type *V. parahaemolyticus* (Fig. S5). There was a total of 33 substrates that the *luxO* mutant showed a defect in compared to the wild-type, seven substrates of which showed a defect only in the *luxO* mutant. The *aphA* mutant showed a significant defect in 30 substrates, five of which were unique to the mutant while 13 carbon sources showed defects also in the *luxO* (Fig. S5). Thus, there were 25 carbon substrates that the *luxO* and *aphA* mutants showed a growth defect whereas the *opaR* mutant did not show a defect in these substrates. These 25 carbon sources included 6 amino acids or their derivatives, 4 dipeptides, 7 sugars, 2 nucleosides, 1 TCA cycle metabolite and 5 miscellaneous carbon sources (Fig. S5). The most significant growth defects in the *luxO* mutant were growth on amino acids and their dipeptide derivatives; L-Aspartic acid, Glycyl-L-Aspartic acid, Glycyl-L-Glutamic, Glycyl L- Proline acid, L-Serine and L-Threonine (Fig. S5). The *luxO* and *aphA* mutants also showed notable defects in L-Glutamic acid and L-Arginine, 2 TCA cycle metabolites (Pyruvic acid and α -Keto-Glutaric acid) and 2 polysaccharides (Glycogen and inulin). We confirmed many of these growth defects by examining the growth pattern of the QS mutants in 12 of the carbon sources (Fig. S6). The *opaR* mutant did not show a defect in these carbon sources and grew similar to wild-type (Fig. S6). These data suggest that the QS regulators may play a key role in regulation of cell metabolism. In addition, considering many of these carbon sources are components of intestinal mucus, which is the primary carbon source available for the bacteria *in vivo*, this disadvantage could contribute to these mutants being out-competed by the wild-type *in vivo*.

Deletion of *opaR* leads to increased metabolic fitness in intestinal mucus and its components. Intestinal mucus is composed of glycoproteins known as mucins that are comprised of 80% oligosaccharide and 20% protein. The main sugars in mucin include fucose,

galactose, mannose, sialic acid, N-acetyl glucosamine, and N-acetyl galactosamine, as well as arabinose, ribose, gluconate, galacturonate, and glucuronate. The three main amino acids that make up the protein core of mucin are serine, threonine and proline (62-66). From genomic analysis, we known that *V. parahaemolyticus* cannot utilize fucose, sialic acid, or galacturonate, and only clinical strains can utilize arabinose. We examined growth of the *luxO*, *aphA* and *opaR* mutants on M9 supplemented individual mucus sugars as the sole carbon source (**Fig. S6**). These data demonstrate that the *luxO* and *aphA* mutants had significantly longer lag phases than wild-type when grown on these substrates. These longer lag phases indicate that these mutants would be at a significant disadvantage at utilizing mucus as a carbon source in comparison to the wild-type strain.

In order to assess whether the metabolic fitness effects could account for the defect of the *luxO* and *aphA* mutant *in vivo*, we performed *in vitro* competition assays in M9 supplemented with mucus (M9M) or M9 with individual mucus sugars as sole carbon sources (**Fig. 5**). We observed that the *luxO* mutant was out-competed in intestinal mucus with a CI of 0.6 (**Fig. 5**) and mucus sugars gluconate, ribose and arabinose with a CI of 0.3, 0.24 and 0.25 (**Fig. 5**). The *aphA* mutant was also significantly out-competed by the wild-type in intestinal mucus with a CI of 0.59 and mucus sugars ribose and arabinose with a CI of 0.67 and 0.66 respectively (**Fig. 5**). In addition, the competitive indices for the *opaR* mutant in *in vitro* competition assays showed the mutant significantly out-competed the wild-type in intestinal mucus with a CI of 1.6 (**Fig. 5**). The *opaR* mutant also significantly out-competed wild-type in individual mucus sugars; mannose, ribose and arabinose with a CI of 1.6, 1.6 and 1.5 respectively (**Fig. 5**). Overall, the *in vitro* metabolic assays suggest that not only is the presence of *aphA* important to the cells, in part due to its regulation of *opaR*, but also induced expression of *opaR* can have a detrimental effect.

483 While constitutive expression of *opaR* results in a fitness defect (*luxO* mutant), deletion of *opaR*
484 provides a fitness advantage (*opaR* mutant) *in vitro*.

485 **OpaR binding sites in the promoter regions of carbon transport and metabolism genes.**

486 Both the *luxO* and *aphA* mutants have a constitutively expressed *opaR* and a repressed *aphA*. We
487 wanted to determine whether the observed *in vitro* growth phenotypes were due to direct or
488 indirect regulation of metabolism and transporter genes by OpaR. First, we performed
489 bioinformatics analysis to identify putative binding sites for OpaR in the promoter regions of 89
490 metabolism and transporter genes. We choose genes that were involved in the transport and
491 metabolism of carbon sources that showed different growth patterns between wild-type and
492 mutants in the phenotypic arrays. The MOODS tool was used to identify OpaR and AphA
493 binding sites using the consensus sequence and position frequency matrix identified by Zhang et
494 al (33) and Sun et al (53). In this analysis, we identified 55 promoter regions with strong binding
495 sites ($P \leq 0.005$ and $>90\%$ probability) for OpaR (**Table S5**). Interestingly the same analysis
496 for AphA consensus binding sequence only identified 9 putative AphA binding sites suggesting
497 that OpaR is the main QS regulator of metabolism (**Table S5**). Of the 55 putative OpaR binding
498 sites, 28 OpaR binding sites were in promoter regions of operons and 27 binding sites were in
499 single gene promoter regions. These included genes for arabinose, ribose, glucose, maltose,
500 trehalose, mannitol, mannose, glycogen, glycerol, cellobiose and spermidine/putrescine
501 transport and/or metabolism. Putative OpaR binding sites were identified also in genes for a
502 general amino acid transport (ORFs VP0008-VP0006, VP1620), thymidine, uridine, serine,
503 aspartate, fumarate, glutarate, arginine, histidine, phenylalanine, tyrosine and tryptophan
504 transport and/or metabolism. In contrast, of the 89 promoter regions examined for AphA binding
505 sites only 9 promoter regions showed strong binding sites (probability $>90\%$), which included

mannose (VPA1424-VPA1425), arabinose (VPA1673-VPA1671), and glycogen (VPA1620) transport and/or metabolism genes (**Table S6**).

In order to validate the bioinformatics analysis of putative OpaR binding sites, we purified OpaR to homogeneity and performed EMSAs on five representative target promoter regions. The five targets were comprised of an amino acid transporter promoter region VP0008-VP0006, the polyamine putrescine cluster VP1779-VP1771, two sugar transporter promoter regions, mannitol (VPA0500-VPA0501) and ribose (VPA1087-VPA1084) and a promoter region for mannose transport and metabolism cluster (VPA1424-VPA1425). The glucose-specific PTS VPA1667 probe, was included as a negative control as it did not have any predicted OpaR binding sites. (**Fig. 6**). For the PVP0008, OpaR bound to the 323-bp DNA probe with increasing concentration of OpaR protein (0-2.7 μ M). Similarly, promoter regions PVP1779 (244-bp), PVPA1087 (333-bp), PVPA0500 (360-bp) and PVPA1424 (350-bp) were bound by OpaR in a concentration dependent manner (**Fig. 6**). The negative DNA control target remained unbound by OpaR at the highest concentrations tested (**Fig. 6**). These data demonstrate that OpaR binding is specific and that OpaR regulates the expression of these targets indicating that it plays a direct role in cell metabolism.

Discussion

In this study, we examined the role of QS regulators in *V. parahaemolyticus* pathogenesis, specifically their role in intestinal colonization. The *in vivo* colonization data show that the QS regulators are essential for efficient colonization. RNA-Seq transcriptome data between the *luxO* mutant and wild-type cells showed global gene expression differences. A striking feature of this data is the number of genes involved in cell metabolism and transport that

were downregulated in the *luxO* mutant compared to wild-type. These included genes required for transport and metabolism of substrates present in intestinal mucus, one of the main nutrient source *in vivo*. The gene expression data suggested that the *luxO* mutant could have metabolic defects based on the down regulation of key metabolism genes. Competition for intestinal nutrients and the ability to utilize intestinal mucus as a carbon and energy source has been shown to be important for successful colonization of intestinal bacteria (67-70). Phenotypic array data showed that the deletion of *luxO* resulted in metabolic defects, with the mutant demonstrating a defect in growth on a number of carbon sources. This was also showed to be the case for the *aphA* mutant, which showed a growth defect compared to wild-type in 25 carbon sources. The carbon substrates in which the mutants showed defects were comprised of nearly equal number of sugars, organic acids and peptides indicating that not just one pathway was affected. Some of the most significant growth defects were in the utilization of amino acids and amino acid derivatives, key intermediates in central metabolism. The *luxO* mutant also had a defect in *in vitro* competition assays in mucus. This is not too surprising given that mucus is made of mainly the glycoprotein mucin and is therefore rich in amino acids as well as sugars (63-66). Neither the *aphA* nor the *opaR* mutants demonstrated a dramatic *in vitro* metabolic fitness effects compared to the *luxO* mutant although each had slightly different growth patterns in one or two carbon sources. One scenario to explain these differences is that in the *luxO* mutant, *aphA* expression is down as is *qrr* expression and *opaR* expression is highly induced. In the *aphA* mutant, *opaR* is induced, but so too should be the *qrrs*, which are negatively regulated by AphA in *V. harveyi*. Thus knocking out both *aphA* and *qrr* expression is more detrimental than just knocking out *aphA* alone. This suggests that there may be dual regulation of genes involved in metabolism and/or additional roles for the Qrrs.

551 A transcriptome study of *Pseudomonas aeruginosa* over 10 years ago demonstrated that
552 the QS activated regulon was over represented by genes involved in intermediate central
553 metabolism (71). They showed that the QS repressed regulon showed carbohydrate utilization
554 and nutrient transport genes were the most abundant representatives (71). A more recent study in
555 the same species demonstrated a global impact of QS on the metabolome and proposed that QS
556 plays a key role in metabolic rewiring of the cell under certain conditions (72). A study
557 examining the targets of LuxR homologues in *Brucella* an intracellular pathogen, identified a
558 large number of proteins involved in metabolic pathways such as central metabolism or amino
559 acid metabolism, respiration, transport of amino acids and sugars that were under the control of
560 QS regulators (73). QS control of metabolic pathways that affects fitness has also been shown in
561 *Burkholderia* species (74). Hwang and colleagues showed that QS regulates oxalate synthesis to
562 counteract alkalization of the growth medium and was essential for fitness (74, 75). More
563 recently this same group has demonstrated that the QS master regulator QsmR down regulates
564 glucose transport, substrate-level and oxidative phosphorylation and nucleotide biosynthesis
565 acting as a metabolic brake on individuals as the population increases (75). Evidence for a role
566 for LuxR in metabolism also comes from *Vibrio* species. In *V. harveyi*, it was demonstrated that
567 the *argA*, *purM*, *lysE*, and *rluA* promoter regions were LuxR dependent, genes involved in
568 arginine and purine biosynthesis, amino acid efflux, and pseudouridine synthesis, respectively
569 (76). In addition, it was demonstrated in *V. fischeri* that QS AinS signaling is essential for
570 control of the acetate switch and this regulation is mediated through the LuxR homolog LitR
571 (77). A recent study in *V. cholerae* showed that the QS LuxR homolog HapR regulated chitin
572 metabolism that provided predator grazing resistance in biofilms. They showed that 19 of 22

573 genes involved in GlcNAc catabolism were repressed in a *hapR* mutant compared to wild-type
574 (78).

575 QS regulators are required for both population level and individual control of gene
576 expression, which corresponds to stationary phase and early exponential growth phases
577 respectively, during which availability of the type and amount of nutrients is very different.
578 Thus, the involvement of QS regulators controlling expression of transporter and metabolism
579 genes makes biological sense. The *luxO* and *aphA* mutants had an *in vivo* defect that correlates to
580 reduced metabolic fitness. In both these mutants OpaR is highly expressed, which suggests that
581 OpaR could be a direct or indirect negative regulator of cell metabolism. Our RNA-seq data
582 revealed that in the *luxO* mutant 60% of downregulated were involved in transport and
583 metabolism. In addition, in the *luxO* mutant a number of regulators that could be involved in
584 regulation of metabolism were also downregulated. These included genes belonging to the LysR
585 family of proteins, which have been shown to regulate a diverse set of genes including those
586 involved in metabolism (79), the AraC/XylS family of transcriptional regulators, which are
587 predominantly involved in the regulation of carbon metabolism (80). Interestingly, we also found
588 that the DNA-binding protein Fis (VP2885) was slightly upregulated in the *luxO* mutant (1.62-
589 fold, $P_{adj} < 0.0001$). Fis is a known global regulator of metabolism. In *Salmonella enterica*, Fis
590 was shown to negatively regulate genes contributing to metabolism in the mammalian gut (81).
591 In addition, the Hfq-binding sRNA Spot 42 was upregulated in the *V. parahaemolyticus luxO*
592 mutant. In *E. coli*, Spot 42 plays an essential role as a regulator in carbohydrate metabolism and
593 uptake, and its expression is activated by glucose and inhibited by CRP. Spot 42 was shown to
594 be a negative regulator of metabolism of many sugars in both *E. coli* and *Vibrio (Allivibrio)*
595 *salmonicida* (82-85). A second sRNA, VrrA was also induced in the *V. parahaemolyticus luxO*

mutant. In *V. cholerae*, studies showed that a *vrpA* mutant had a 5-fold increased ability to colonize infant mice (86). *VrrA* downregulates outer membrane proteins, *OmpA* and *OmpT*, the stationary phase survival factor *Vrp* and biofilm matrix protein *RbmC* in *V. cholerae* (87, 88).

To determine the possible extent of direct regulation of cell metabolism and transport by the QS regulators we performed bioinformatics analysis and examined 89 regulatory regions of metabolism genes for the presence of putative *OpaR* and *AphA* binding sites. We identified 55 loci that contained strong putative *OpaR* binding sites and only 9 *AphA* putative binding sites. From the 55 loci with putative *OpaR* binding sites, we chose five representatives to examine further using EMSAs; a general amino acid transporter (VP0008-VP0006), ribose (VPA1087-VPA1084) and mannose (VPA1424-VPA1425) metabolism and transporter, mannitol (VPA0500-VPA0501) and putrescine metabolism (VP1771-VP1779) regulatory regions. We investigated the regulatory region of the general amino acid transporter since both microarray and RNA-seq analysis showed repression of these genes by *OpaR* (30, 42). Our binding analysis confirmed that indeed *OpaR* does bind to the regulatory region of this operon. We examined the ribose and mannose regulatory regions since these sugars are important mucus sugars and we observed growth defects in these sugars in the *luxO* and *aphA* mutants compared to wild-type. We investigated binding to the regulatory region of the transporter of sugar alcohol mannitol because it had one of the strongest putative *OpaR* binding sites. The polyamine putrescine cluster VP1779-VP1771 is involved in putrescine metabolism and contains genes that shuttle into multiple metabolic pathways. All the genes in this pathway were downregulated in the *luxO* mutant compared to wild-type, and this was confirmed by qPCR and EMSA analysis showed binding of *OpaR* to the regulatory region. These data indicate that *OpaR* is a negative regulator of putrescine metabolism. Thus, EMSA analysis demonstrated binding to all five regulatory

619 regions and no binding to the negative control using the highest concentration of OpaR. These
620 data demonstrate a direct role for OpaR in cell metabolism and suggest that this role may be
621 more prevalent than previously appreciated.

622

623 ACKNOWLEDGEMENTS

624 We thank Nathan McDonald, Abish Regmi, Joe Borowski, Gwen Gregory and Aoife Boyd for
625 reviewing the manuscript and helpful discussions. This work was supported in part by a National
626 Science Foundation grant DEB-0844409 to EFB and departmental funds.

627 REFERENCES

- 628 1. **Hondo S, Goto I, Minematsu I, Ikeda N, Asano N, Ishibashi M, Kinoshita Y,**
629 **Nishibuchi N, Honda T, Miwatani T.** 1987. Gastroenteritis due to Kanagawa negative
630 *Vibrio parahaemolyticus*. *Lancet* **1**:331-332.
- 631 2. **Daniels NA, MacKinnon L, Bishop R, Altekruze S, Ray B, Hammond RM,**
632 **Thompson S, Wilson S, Bean NH, Griffin PM, Slutsker L.** 2000. *Vibrio*
633 *parahaemolyticus* infections in the United States, 1973-1998. *J. Infect. Dis.* **181**:1661-
634 1666.
- 635 3. **McLaughlin JB, DePaola A, Bopp CA, Martinek KA, Napolilli NP, Allison CG,**
636 **Murray SL, Thompson EC, Bird MM, Middaugh JP.** 2005. Outbreak of *Vibrio*
637 *parahaemolyticus* gastroenteritis associated with Alaskan oysters. *N Engl J Med*
638 **353**:1463-1470.
- 639 4. **Nair GB, Ramamurthy T, Bhattacharya SK, Dutta B, Takeda Y, Sack DA.** 2007.
640 Global dissemination of *Vibrio parahaemolyticus* serotype O3:K6 and its serovariants.
641 *Clin Microbiol Rev* **20**:39-48.
- 642 5. **Qadri F, Alam MS, Nishibuchi M, Rahman T, Alam NH, Chisti J, Kondo S,**
643 **Sugiyama J, Bhuiyan NA, Mathan MM, Sack DA, Nair GB.** 2003. Adaptive and
644 inflammatory immune responses in patients infected with strains of *Vibrio*
645 *parahaemolyticus*. *J Infect Dis* **187**:1085-1096.
- 646 6. **Makino K, Oshima K, Kurokawa K, Yokoyama K, Uda T, Tagomori K, Iijima Y,**
647 **Najima M, Nakano M, Yamashita A, Kubota Y, Kimura S, Yasunaga T, Honda T,**
648 **Shinagawa H, Hattori M, Iida T.** 2003. Genome sequence of *Vibrio parahaemolyticus*:
649 a pathogenic mechanism distinct from that of *V cholerae*. *Lancet* **361**:743-749.
- 650 7. **Ham H, Orth K.** 2012. The role of type III secretion system 2 in *Vibrio*
651 *parahaemolyticus* pathogenicity. *J Microbiol* **50**:719-725.

- 652 8. **O'Boyle N, Boyd A.** 2014. Manipulation of intestinal epithelial cell function by the cell
653 contact-dependent type III secretion systems of *Vibrio parahaemolyticus*. *Front Cell*
654 *Infect Microbiol* **3**:114.
- 655 9. **Hiyoshi H, Kodama T, Iida T, Honda T.** 2010. Contribution of *Vibrio*
656 *parahaemolyticus* virulence factors to cytotoxicity, enterotoxicity, and lethality in mice.
657 *Infect Immun* **78**:1772-1780.
- 658 10. **Park KS, Ono T, Rokuda M, Jang MH, Okada K, Iida T, Honda T.** 2004. Functional
659 characterization of two type III secretion systems of *Vibrio parahaemolyticus*. *Infect*
660 *Immun* **72**:6659-6665.
- 661 11. **Pineyro P, Zhou X, Orfe LH, Friel PJ, Lahmers K, Call DR.** 2010. Development of
662 two animal models to study the function of *Vibrio parahaemolyticus* type III secretion
663 systems. *Infect Immun* **78**:4551-4559.
- 664 12. **Ritchie JM, Rui H, Zhou X, Iida T, Kodoma T, Ito S, Davis BM, Bronson RT,**
665 **Waldor MK.** 2012. Inflammation and disintegration of intestinal villi in an experimental
666 model for *Vibrio parahaemolyticus*-induced diarrhea. *PLoS Pathog* **8**:e1002593.
- 667 13. **Whitaker WB, Parent MA, Boyd A, Richards GP, Boyd EF.** 2012. The *Vibrio*
668 *parahaemolyticus* ToxRS regulator is required for stress tolerance and colonization in a
669 novel orogastric streptomycin-induced adult murine model. *Infect Immun* **80**:1834-1845.
- 670 14. **Whitaker WB, Richards GP, Boyd EF.** 2014. Loss of Sigma Factor RpoN Increases
671 Intestinal Colonization of *Vibrio parahaemolyticus* in an Adult Mouse Model. *Infect*
672 *Immun* **82**:544-556.
- 673 15. **Haines-Menges B, Whitaker WB, Boyd EF.** 2014. Alternative sigma factor RpoE is
674 important for *Vibrio parahaemolyticus* cell envelope stress response and intestinal
675 colonization. *Infect Immun* **82**:3667-3677.
- 676 16. **Hubbard TP, Chao MC, Abel S, Blondel CJ, Abel Zur Wiesch P, Zhou X, Davis**
677 **BM, Waldor MK.** 2016. Genetic analysis of *Vibrio parahaemolyticus* intestinal
678 colonization. *Proc Natl Acad Sci U S A* **113**:6283-6288.
- 679 17. **Fuqua WC, Winans SC, Greenberg EP.** 1994. Quorum sensing in bacteria: the LuxR-
680 LuxI family of cell density-responsive transcriptional regulators. *J Bacteriol* **176**:269-
681 275.
- 682 18. **Hardman AM, Stewart GS, Williams P.** 1998. Quorum sensing and the cell-cell
683 communication dependent regulation of gene expression in pathogenic and non-
684 pathogenic bacteria. *Antonie Van Leeuwenhoek* **74**:199-210.
- 685 19. **Hastings JW, Nealson KH.** 1977. Bacterial bioluminescence. *Annu Rev Microbiol*
686 **31**:549-595.
- 687 20. **Bassler BL.** 1999. How bacteria talk to each other: regulation of gene expression by
688 quorum sensing. *Curr Opin Microbiol* **2**:582-587.
- 689 21. **Bassler BL, Wright M, Showalter RE, Silverman MR.** 1993. Intercellular signalling in
690 *Vibrio harveyi*: sequence and function of genes regulating expression of luminescence.
691 *Mol Microbiol* **9**:773-786.
- 692 22. **Ng WL, Bassler BL.** 2009. Bacterial quorum-sensing network architectures. *Annu Rev*
693 *Genet* **43**:197-222.
- 694 23. **Miyamoto CM, Dunlap PV, Ruby EG, Meighen EA.** 2003. LuxO controls *luxR*
695 expression in *Vibrio harveyi*: evidence for a common regulatory mechanism in *Vibrio*.
696 *Mol Microbiol* **48**:537-548.

- 697 24. **Gray KM, Passador L, Iglewski BH, Greenberg EP.** 1994. Interchangeability and
698 specificity of components from the quorum-sensing regulatory systems of *Vibrio fischeri*
699 and *Pseudomonas aeruginosa*. *J Bacteriol* **176**:3076-3080.
- 700 25. **McCarter LL.** 1998. OpaR, a homolog of *Vibrio harveyi* LuxR, controls opacity of
701 *Vibrio parahaemolyticus*. *J Bacteriol* **180**:3166-3173.
- 702 26. **Miller MB, Skorupski K, Lenz DH, Taylor RK, Bassler BL.** 2002. Parallel quorum
703 sensing systems converge to regulate virulence in *Vibrio cholerae*. *Cell* **110**:303-314.
- 704 27. **Jaques S, McCarter LL.** 2006. Three new regulators of swarming in *Vibrio*
705 *parahaemolyticus*. *J Bacteriol* **188**:2625-2635.
- 706 28. **Milton DL.** 2006. Quorum sensing in vibrios: complexity for diversification. *Int J Med*
707 *Microbiol* **296**:61-71.
- 708 29. **Hammer BK, Bassler BL.** 2003. Quorum sensing controls biofilm formation in *Vibrio*
709 *cholerae*. *Mol Microbiol* **50**:101-104.
- 710 30. **Gode-Potratz CJ, McCarter LL.** 2011. Quorum sensing and silencing in *Vibrio*
711 *parahaemolyticus*. *J Bacteriol* **193**:4224-4237.
- 712 31. **Henke JM, Bassler BL.** 2004. Quorum sensing regulates type III secretion in *Vibrio*
713 *harveyi* and *Vibrio parahaemolyticus*. *J Bacteriol* **186**:3794-3805.
- 714 32. **Wang L, Zhou D, Mao P, Zhang Y, Hou J, Hu Y, Li J, Hou S, Yang R, Wang R, Qiu**
715 **J.** 2013. Cell density- and quorum sensing-dependent expression of type VI secretion
716 system 2 in *Vibrio parahaemolyticus*. *PLoS One* **8**:e73363.
- 717 33. **Zhang Y, Qiu Y, Tan Y, Guo Z, Yang R, Zhou D.** 2012. Transcriptional regulation of
718 opaR, qrr2-4 and aphA by the master quorum-sensing regulator OpaR in *Vibrio*
719 *parahaemolyticus*. *PLoS One* **7**:e34622.
- 720 34. **Zhou D, Yan X, Qu F, Wang L, Zhang Y, Hou J, Hu Y, Li J, Xin S, Qiu J, Yang R,**
721 **Mao P.** 2013. Quorum sensing modulates transcription of cpsQ-mfpABC and mfpABC
722 in *Vibrio parahaemolyticus*. *Int J Food Microbiol* **166**:458-463.
- 723 35. **Lilley BN, Bassler BL.** 2000. Regulation of quorum sensing in *Vibrio harveyi* by LuxO
724 and sigma-54. *Mol Microbiol* **36**:940-954.
- 725 36. **Tu KC, Bassler BL.** 2007. Multiple small RNAs act additively to integrate sensory
726 information and control quorum sensing in *Vibrio harveyi*. *Genes Dev* **21**:221-233.
- 727 37. **Lenz DH, Mok KC, Lilley BN, Kulkarni RV, Wingreen NS, Bassler BL.** 2004. The
728 small RNA chaperone Hfq and multiple small RNAs control quorum sensing in *Vibrio*
729 *harveyi* and *Vibrio cholerae*. *Cell* **118**:69-82.
- 730 38. **Bardill JP, Zhao X, Hammer BK.** 2011. The *Vibrio cholerae* quorum sensing response
731 is mediated by Hfq-dependent sRNA/mRNA base pairing interactions. *Mol Microbiol*
732 **80**:1381-1394.
- 733 39. **van Kessel JC, Rutherford ST, Shao Y, Utria AF, Bassler BL.** 2013. Individual and
734 combined roles of the master regulators AphA and LuxR in control of the *Vibrio harveyi*
735 quorum-sensing regulon. *J Bacteriol* **195**:436-443.
- 736 40. **Rutherford ST, van Kessel JC, Shao Y, Bassler BL.** 2011. AphA and LuxR/HapR
737 reciprocally control quorum sensing in vibrios. *Genes Dev* **25**:397-408.
- 738 41. **Wang L, Ling Y, Jiang H, Qiu Y, Qiu J, Chen H, Yang R, Zhou D.** 2013. AphA is
739 required for biofilm formation, motility, and virulence in pandemic *Vibrio*
740 *parahaemolyticus*. *Int J Food Microbiol* **160**:245-251.

- 741 42. Kernell Burke A, Guthrie LT, Modise T, Cormier G, Jensen RV, McCarter LL,
742 Stevens AM. 2015. OpaR controls a network of downstream transcription factors in
743 *Vibrio parahaemolyticus* BB22OP. PLoS One **10**:e0121863.
- 744 43. Salomon D, Klimko JA, Orth K. 2014. H-NS regulates the *Vibrio parahaemolyticus*
745 type VI secretion system 1. Microbiology **160**:1867-1873.
- 746 44. Gu D, Liu H, Yang Z, Zhang Y, Wang Q. 2016. Chromatin Immunoprecipitation
747 Sequencing Technology Reveals Global Regulatory Roles of Low-Cell-Density Quorum-
748 Sensing Regulator AphA in the Pathogen *Vibrio alginolyticus*. J Bacteriol **198**:2985-
749 2999.
- 750 45. Skorupski K, Taylor RK. 1999. A new level in the *Vibrio cholerae* ToxR virulence
751 cascade: AphA is required for transcriptional activation of the tcpPH operon. Mol
752 Microbiol **31**:763-771.
- 753 46. Yang M, Frey EM, Liu Z, Bishar R, Zhu J. 2010. The virulence transcriptional
754 activator AphA enhances biofilm formation by *Vibrio cholerae* by activating expression
755 of the biofilm regulator VpsT. Infect Immun **78**:697-703.
- 756 47. Whitaker WB, Parent MA, Naughton LM, Richards GP, Blumerman SL, Boyd EF.
757 2010. Modulation of responses of *Vibrio parahaemolyticus* O3:K6 to pH and temperature
758 stresses by growth at different salt concentrations. Appl Environ Microbiol **76**:4720-
759 4729.
- 760 48. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. 1989. Engineering hybrid genes
761 without the use of restriction enzymes: gene splicing by overlap extension. Gene **77**:61-
762 68.
- 763 49. Kalburge SS, Whitaker WB, Boyd EF. 2014. High-salt preadaptation of *Vibrio*
764 *parahaemolyticus* enhances survival in response to lethal environmental stresses. J Food
765 Prot **77**:246-253.
- 766 50. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-
767 PCR. Nucleic Acids Res **29**:e45.
- 768 51. Cohen PS, Laux DC. 1995. Bacterial adhesion to and penetration of intestinal mucus in
769 vitro. Methods Enzymol **253**:309-314.
- 770 52. Leatham MP, Stevenson SJ, Gauger EJ, Krogfelt KA, Lins JJ, Haddock TL, Autieri
771 SM, Conway T, Cohen PS. 2005. Mouse intestine selects nonmotile flhDC mutants of
772 *Escherichia coli* MG1655 with increased colonizing ability and better utilization of
773 carbon sources. Infect Immun **73**:8039-8049.
- 774 53. Sun F, Zhang Y, Wang L, Yan X, Tan Y, Guo Z, Qiu J, Yang R, Xia P, Zhou D.
775 2012. Molecular characterization of direct target genes and cis-acting consensus
776 recognized by quorum-sensing regulator AphA in *Vibrio parahaemolyticus*. PLoS One
777 **7**:e44210.
- 778 54. Korhonen J, Martinmaki P, Pizzi C, Rastas P, Ukkonen E. 2009. MOODS: fast
779 search for position weight matrix matches in DNA sequences. Bioinformatics **25**:3181-
780 3182.
- 781 55. Pizzi C, Rastas P, Ukkonen E. 2011. Finding significant matches of position weight
782 matrices in linear time. IEEE/ACM Trans Comput Biol Bioinform **8**:69-79.
- 783 56. Mao F, Dam P, Chou J, Oltman V, Xu Y. 2009. DOOR: a database for prokaryotic
784 operons. Nucleic Acids Res **37**:D459-463.

57. **Thorvaldsdottir H, Robinson JT, Mesirov JP.** 2013. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform* **14**:178-192.
58. **Carpenter MR, Rozovsky S, Boyd EF.** 2015. Pathogenicity Island Cross Talk Mediated by Recombination Directionality Factors Facilitates Excision from the Chromosome. *J Bacteriol* **198**:766-776.
59. **Enos-Berlage JL, Guvener ZT, Keenan CE, McCarter LL.** 2005. Genetic determinants of biofilm development of opaque and translucent *Vibrio parahaemolyticus*. *Mol Microbiol* **55**:1160-1182.
60. **Guvener ZT, McCarter LL.** 2003. Multiple regulators control capsular polysaccharide production in *Vibrio parahaemolyticus*. *J Bacteriol* **185**:5431-5441.
61. **Liu YW, Denkmann K, Kosciow K, Dahl C, Kelly DJ.** 2013. Tetrathionate stimulated growth of *Campylobacter jejuni* identifies a new type of bi-functional tetrathionate reductase (TsdA) that is widely distributed in bacteria. *Mol Microbiol* **88**:173-188.
62. **Chang DE, Smalley DJ, Tucker DL, Leatham MP, Norris WE, Stevenson SJ, Anderson AB, Grissom JE, Laux DC, Cohen PS, Conway T.** 2004. Carbon nutrition of *Escherichia coli* in the mouse intestine. *Proc Natl Acad Sci U S A* **101**:7427-7432.
63. **Clamp JR, Fraser G, Read AE.** 1981. Study of the carbohydrate content of mucus glycoproteins from normal and diseased colons. *Clin Sci (Lond)* **61**:229-234.
64. **Conway T, Krogfelt KA, Cohen PS.** 2004. The Life of Commensal *Escherichia coli* in the Mammalian Intestine. *EcoSal Plus* **1**.
65. **Corazziari ES.** 2009. Intestinal mucus barrier in normal and inflamed colon. *J Pediatr Gastroenterol Nutr* **48 Suppl 2**:S54-55.
66. **Fabich AJ, Jones SA, Chowdhury FZ, Cernosek A, Anderson A, Smalley D, McHargue JW, Hightower GA, Smith JT, Autieri SM, Leatham MP, Lins JJ, Allen RL, Laux DC, Cohen PS, Conway T.** 2008. Comparison of carbon nutrition for pathogenic and commensal *Escherichia coli* strains in the mouse intestine. *Infect Immun* **76**:1143-1152.
67. **Conway T, Cohen PS.** 2015. Commensal and Pathogenic *Escherichia coli* Metabolism in the Gut. *Microbiol Spectr* **3**.
68. **Maltby R, Leatham-Jensen MP, Gibson T, Cohen PS, Conway T.** 2013. Nutritional basis for colonization resistance by human commensal *Escherichia coli* strains HS and Nissle 1917 against *E. coli* O157:H7 in the mouse intestine. *PLoS One* **8**:e53957.
69. **Stecher B, Hardt WD.** 2011. Mechanisms controlling pathogen colonization of the gut. *Curr Opin Microbiol* **14**:82-91.
70. **Donaldson GP, Lee SM, Mazmanian SK.** 2015. Gut biogeography of the bacterial microbiota. *Nat Rev Microbiol* **14**:20-32.
71. **Schuster M, Lostroh CP, Ogi T, Greenberg EP.** 2003. Identification, timing, and signal specificity of *Pseudomonas aeruginosa* quorum-controlled genes: a transcriptome analysis. *J Bacteriol* **185**:2066-2079.
72. **Davenport PW, Griffin JL, Welch M.** 2015. Quorum Sensing Is Accompanied by Global Metabolic Changes in the Opportunistic Human Pathogen *Pseudomonas aeruginosa*. *J Bacteriol* **197**:2072-2082.
73. **Uzureau S, Lemaire J, Delaive E, Dieu M, Gaigneaux A, Raes M, De Bolle X, Letesson JJ.** 2010. Global analysis of quorum sensing targets in the intracellular pathogen *Brucella melitensis* 16 M. *J Proteome Res* **9**:3200-3217.

- 831 74. **Goo E, Majerczyk CD, An JH, Chandler JR, Seo YS, Ham H, Lim JY, Kim H, Lee**
832 **B, Jang MS, Greenberg EP, Hwang I.** 2012. Bacterial quorum sensing, cooperativity,
833 and anticipation of stationary-phase stress. *Proc Natl Acad Sci U S A* **109**:19775-19780.
- 834 75. **An JH, Goo E, Kim H, Seo YS, Hwang I.** 2014. Bacterial quorum sensing and
835 metabolic slowing in a cooperative population. *Proc Natl Acad Sci U S A* **111**:14912-
836 14917.
- 837 76. **Miyamoto CM, Meighen EA.** 2006. Involvement of LuxR, a quorum sensing regulator
838 in *Vibrio harveyi*, in the promotion of metabolic genes: *argA*, *purM*, *lysE* and *rluA*.
839 *Biochim Biophys Acta* **1759**:296-307.
- 840 77. **Studer SV, Mandel MJ, Ruby EG.** 2008. AinS quorum sensing regulates the *Vibrio*
841 *fischeri* acetate switch. *J Bacteriol* **190**:5915-5923.
- 842 78. **Sun S, Tay QX, Kjelleberg S, Rice SA, McDougald D.** 2015. Quorum sensing-
843 regulated chitin metabolism provides grazing resistance to *Vibrio cholerae* biofilms.
844 *ISME J* **9**:1812-1820.
- 845 79. **Maddocks SE, Oyston PC.** 2008. Structure and function of the LysR-type
846 transcriptional regulator (LTTR) family proteins. *Microbiology* **154**:3609-3623.
- 847 80. **Gallegos MT, Schleif R, Bairoch A, Hofmann K, Ramos JL.** 1997. Arac/XylS family
848 of transcriptional regulators. *Microbiol Mol Biol Rev* **61**:393-410.
- 849 81. **Kelly A, Goldberg MD, Carroll RK, Danino V, Hinton JC, Dorman CJ.** 2004. A
850 global role for Fis in the transcriptional control of metabolism and type III secretion in
851 *Salmonella enterica* serovar Typhimurium. *Microbiology* **150**:2037-2053.
- 852 82. **Beisel CL, Storz G.** 2011. Discriminating tastes: physiological contributions of the Hfq-
853 binding small RNA Spot 42 to catabolite repression. *RNA Biol* **8**:766-770.
- 854 83. **Beisel CL, Storz G.** 2012. The base-pairing RNA spot 42 participates in a multioutput
855 feedforward loop to help enact catabolite repression in *Escherichia coli*. *Mol Cell* **41**:286-
856 297.
- 857 84. **Hansen GA, Ahmad R, Hjerde E, Fenton CG, Willassen NP, Haugen P.** 2012.
858 Expression profiling reveals Spot 42 small RNA as a key regulator in the central
859 metabolism of *Aliivibrio salmonicida*. *BMC Genomics* **13**:37.
- 860 85. **Moller T, Franch T, Udesen C, Gerdes K, Valentin-Hansen P.** 2002. Spot 42 RNA
861 mediates discoordinate expression of the *E. coli* galactose operon. *Genes Dev* **16**:1696-
862 1706.
- 863 86. **Song T, Mika F, Lindmark B, Liu Z, Schild S, Bishop A, Zhu J, Camilli A,**
864 **Johansson J, Vogel J, Wai SN.** 2008. A new *Vibrio cholerae* sRNA modulates
865 colonization and affects release of outer membrane vesicles. *Mol Microbiol* **70**:100-111.
- 866 87. **Sabharwal D, Song T, Papenfort K, Wai SN.** 2015. The VrrA sRNA controls a
867 stationary phase survival factor Vrp of *Vibrio cholerae*. *RNA Biol* **12**:186-196.
- 868 88. **Song T, Sabharwal D, Wai SN.** 2010. VrrA mediates Hfq-dependent regulation of
869 OmpT synthesis in *Vibrio cholerae*. *J Mol Biol* **400**:682-688.
- 870
- 871

872

873 **Figure Legends**

874 **Fig. 1. Quorum sensing pathway in *V. parahaemolyticus*.** The sigma 54-dependent response
875 regulator LuxO activates the transcription of the quorum regulatory RNAs (*qrrs*) 1-5. These Qrrs
876 bind to the mRNA of the QS master regulators, blocking the translation of OpaR and promoting
877 the translation of AphA. OpaR and AphA repress the transcription of each other. In a *luxO*
878 mutant indicated by X, no *qrrs* are transcribed and this results in constitutive activation of OpaR
879 and repression of *aphA*. Dashed lines indicate no transcripts made and dashed arrows indicate no
880 regulation, solid lines indicate regulation, arrows indicate positive regulation and hammers
881 indicate negative regulation.

882 **Fig. 2. *In vivo* competition assays.** A 1:1 mixed culture of WBWlacZ and deletion mutants were
883 used to orogastrically infect streptomycin-pretreated adult mice. CFUs were calculated 24 h post
884 infection from the entire gastrointestinal tracts using a blue/white colony selection. Data are
885 pooled from two separate experiments and reported as competitive index (CI) for the *luxO* (n=8),
886 *aphA* (n=10), *opaR* (n=5), *luxO/opaR* (n=10), and *opaR/aphA* (n=7) mutants. The solid line
887 indicates the means. *P* values were calculated using a Welch's unpaired t-test with a 95%
888 confidence interval. Asterisks denote significant differences between the CI of the mutant strains
889 compared with the wild-type strain. *, *P* < 0.05; **, *P* < 0.01; ***, *P* <= 0.001 ****, *P* < 0.0001.

890 **Fig. 3. Expression analysis of quorum sensing master regulators and *qrrs*.** RNA was
891 extracted from wild-type and mutant strains grown in M9 media supplemented with glucose
892 (M9G) to OD 1.0 and analyzed by qPCR in duplicate for each biological replicate. **A.** Bars
893 represent the expression of *opaR* normalized to 16S rRNA in the *luxO*, *rpoN* and *aphA* mutants
894 relative to wild-type cells. **B.** Bars represent the expression of the *aphA* normalized to 16S rRNA

895 in the *luxO*, *rpoN*, and *opaR* mutants relative to wild-type cells. **C.** Bars represent the expression
896 of *qrr 1*, *qrr2*, *qrr3* and *qrr5* normalized to 16S rRNA in $\Delta luxO$. **D.** Bars represent the expression
897 of the *qrr 1*, *qrr2*, *qrr3* and *qrr5* normalized to 16S rRNA in $\Delta rpoN$. *P* values were calculated
898 using an unpaired Student's t-test with a 95% confidence interval. Asterisks denote significant
899 differences in relative gene expression between mutant and wild-type. *, $P < 0.05$; **, $P < 0.01$.

900 **Fig. 4. QPCR validations of RNA Seq Expression in the *luxO* mutant relative to wild-type.**

901 Pre-ribozero treated RNA from the wild-type and the *luxO* mutant was used for cDNA synthesis
902 and expression analyzed by QPCR in duplicate for each biological replicate. **A.** Bars represent
903 the expression of the *opaR*, *aphA*, *qrr1*, *qrr2*, *qrr3* and *qrr5* normalized to 16S rRNA in the *luxO*
904 mutant relative to wild-type cells. **B.** Bars represent the expression of four metabolism genes
905 normalized to 16S rRNA in the *luxO* mutant relative to wild-type. **C.** Bars represent relative
906 expression of T3SS and T6SS genes normalized to 16S rRNA in the *luxO* mutant relative to
907 wild-type cells. *P* values were calculated using an unpaired Student's t-test with a 95%
908 confidence interval. Asterisks denote significant differences in relative gene expression between
909 mutant and wild-type. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$

910 **Fig. 5. In vitro competition assays of *V. parahaemolyticus* wild-type and the QS mutants**

911 *luxO*, *opaR* and *aphA*. In vitro competition assays between the WBWlacZ strain and the mutant
912 strains in mucus and individual mucus sugars. *P* values were calculated using an unpaired
913 Student's t-test with a 95% confidence interval. Asterisks denote significant differences in CI
914 between the mutant strains and the wild-type. *, $P < 0.05$, **, $P < 0.01$, ***, $P < 0.001$

915 **Fig. 6. OpaR binding sites in regulatory regions of metabolism and transporter genes.**

916 Electrophoretic mobility shift assays (EMSAs) of the DNA fragments of promoter regions for

917 VP0008, VP1779, VPA1087, VPA0500, and VPA1424. Varying concentrations of OpaR (0 -3.7
918 μ M) were incubated with DNA substrates corresponding to the promoter region of the following
919 genes starting upstream of the translational ATG start site; VP0008 (PVP0008: DNA probe 323-
920 bp), VP1779 (PVP1779: DNA probe 244-bp), VPA1087 (PVPA1087: DNA probe 333-bp),
921 VPA0500 (PVPA0500): DNA probe 360-bp), and VPA1424 (PVPA1424: DNA probe 350-bp).
922 The DNA fragment from ORF VPA1667 (PVPA1667: DNA probe 308-bp) was used as a
923 negative control. Binding of OpaR was shown for all sites that were identified to contain putative
924 OpaR binding sites by bioinformatics. Ratios indicated above each gel image indicate ratio of
925 DNA: Protein concentrations used in each well. Grey arrows represent unbound DNA and black
926 arrows represent bound DNA. M=marker.

927




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6